Annual Report to the Nation on the Status of Cancer, part II: Recent changes in prostate cancer trends and disease characteristics.
Annual Report to the Nation on the Status of Cancer, part II: Recent changes in prostate cancer trends and disease characteristics.
复制标题
DOI：
10.1002/cncr.31549
复制
发表时间：
2018-07-01
期刊：
影响因子：
6.2
通讯作者：
Penberthy L
中科院分区：
文献类型：
--
作者：
Negoita S;Feuer EJ;Mariotto A;Cronin KA;Petkov VI;Hussey SK;Benard V;Henley SJ;Anderson RN;Fedewa S;Sherman RL;Kohler BA;Dearmon BJ;Lake AJ;Ma J;Richardson LC;Jemal A;Penberthy L
前列腺癌发病率和死亡率的时间趋势归因于筛查模式的变化和治疗的改善（仅死亡率）等因素。这项研究评估了当代国家层面的趋势及其与前列腺特异性抗原（PSA）检测流行率的关系，并根据疾病特征和特定阶段、延迟调整率探索了发病率趋势。联合点回归用于检查2000年至2014年基于人群的美国癌症登记研究中延迟校正的前列腺癌发病率的变化，包括年龄类别、种族和疾病特征，包括分期、PSA、Gleason评分和临床扩展。此外，该分析还包括1975年至2015年期间按种族划分的前列腺癌死亡率趋势以及1987年至2005年期间PSA检测患病率的估计。对于由显著趋势变化点定义的时期，计算年度百分比变化。从2007年起，所有年龄组的前列腺癌总发病率每年下降约6.5%。然而，从2010年到2014年，远端疾病的发病率有所增加。根据诊断时较高的PSA水平或Gleason评分，疾病的发生率没有增加。经过多年的显著下降（从1993年到2013年），整体前列腺癌死亡率趋势从2013年到2015年稳定下来。在PSA检测使用率下降后，晚期疾病的负担增加，前列腺癌死亡率的下降趋于平稳。癌症2018;124：2801 - 2814。© 2018美国癌症协会美国癌症监测界首次对前列腺癌发病率的长期趋势进行了分期分析，并采用延迟调整率。根据全国范围内的癌症登记和生命登记数据，自美国预防服务工作组（US Preventive Services Task Force）建议反对基于前列腺特异性抗原的筛查以来，美国的前列腺癌远端期疾病的发病率有所增加，所有分期的死亡率均趋于平稳（另见第2785 - 800和2690 - 2页）。
Temporal trends in prostate cancer incidence and death rates have been attributed to changing patterns of screening and improved treatment (mortality only), among other factors. This study evaluated contemporary national‐level trends and their relations with prostate‐specific antigen (PSA) testing prevalence and explored trends in incidence according to disease characteristics with stage‐specific, delay‐adjusted rates. Joinpoint regression was used to examine changes in delay‐adjusted prostate cancer incidence rates from population‐based US cancer registries from 2000 to 2014 by age categories, race, and disease characteristics, including stage, PSA, Gleason score, and clinical extension. In addition, the analysis included trends for prostate cancer mortality between 1975 and 2015 by race and the estimation of PSA testing prevalence between 1987 and 2005. The annual percent change was calculated for periods defined by significant trend change points. For all age groups, overall prostate cancer incidence rates declined approximately 6.5% per year from 2007. However, the incidence of distant‐stage disease increased from 2010 to 2014. The incidence of disease according to higher PSA levels or Gleason scores at diagnosis did not increase. After years of significant decline (from 1993 to 2013), the overall prostate cancer mortality trend stabilized from 2013 to 2015. After a decline in PSA test usage, there has been an increased burden of late‐stage disease, and the decline in prostate cancer mortality has leveled off. Cancer 2018;124:2801‐2814. © 2018 American Cancer Society For the first time, the US cancer surveillance community has performed an analysis of long‐term trends in the incidence of prostate cancer by stage with delay‐adjusted rates. According to nationwide cancer registry and vital registration data, prostate cancer incidence rates for distant‐stage disease have increased and mortality rates for all stages combined have leveled off in the United States since the US Preventive Services Task Force recommendations against prostate‐specific antigen–based screening.See also pages 2785‐800 and 2690‐2.
登录
查看更多内容
影响因子：
5.6
作者：
Epstein, Jonathan I.;Amin, Mahul B.;Humphrey, Peter A.
通讯作者：
Humphrey, Peter A.
影响因子：
1.7
作者：
Huang, Lan;Midthune, Douglas;Feuer, Eric J.
通讯作者：
Feuer, Eric J.
影响因子：
6.2
作者：
Gulati, Roman;Tsodikov, Alex;Etzioni, Ruth;Hunter-Merrill, Rachel A.;Gore, John L.;Mariotto, Angela B.;Cooperberg, Matthew R.
通讯作者：
Cooperberg, Matthew R.
影响因子：
5.5
作者：
Berkowitz Z;Li J;Richards TB;Marcus PM
通讯作者：
Marcus PM
影响因子：
6.6
作者：
Han, M;Partin, AW;Walsh, PC
通讯作者：
Walsh, PC